What is Bicara Therapeutics's cumulative cost basis?

Bicara Therapeutics (BCAX) reported cumulative cost basis of $216.53M in Q1 2026.

Bicara Therapeutics BCAX Cumulative Cost Basis

Cumulative Cost Basis at other companies

AmgenAMGN

——

Inhibrx Biosciences, Inc.INBX

——

Arcus BiosciencesRCUS

——

Nuvation BioNUVB

——

Vir Biotechnology, Inc.VIR

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's cumulative cost basis?: Bicara Therapeutics (BCAX) reported cumulative cost basis of $216.53M in Q1 2026.